Results 151 to 160 of about 68,908 (269)

Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 1, January 2026.
ABSTRACT Modafinil is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnoea (OSA), and shift work sleep disorder (SWSD), but its widespread off‐label use raises safety concerns. We evaluated the risk of adverse events (AEs) associated with both labelled and off‐label use of modafinil.
Jaehee Jung, Jaeyoon Youm, Jihyun Kang, Ah‐Young Kim, Jae Kyung Suh, Hye‐Young Kang   +5 more
wiley   +1 more source

Physiologically‐based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate [PDF]

, 2023
Walaa Yousef Bassyouni Mahdy, Kazuhiro Yamamoto, Takahiro Ito, Naoko Fujiwara, Kazumichi Fujioka, Tadasu Horai, Ikuo Otsuka, Hitomi Imafuku, Tomohiro Omura, Kazumoto Iijima, Ikuko Yano   +10 more
openalex   +1 more source

A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 94-102, January 2026.
Abstract Aims Antipsychotics increase metabolic syndrome (MetSyn) and diabetes risk. Preclinical and translational research data suggest that ulotaront, an investigational trace amine‐associated receptor 1 (TAAR1) agonist, may have beneficial metabolic effects.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu‐Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Edward Jackson, Kenneth Koblan, Seth C. Hopkins   +11 more
wiley   +1 more source

Determination of Trace Amounts of Risperidone in Human Urine Sample by Hollow Fiber Liquid-Phase Microextraction Combined with High Performance Liquid Chromatography

, 2015
Gaianeh Charmahali, Mahnaz Qomi, Shadi Akhavan, Meghedi Chaharmahali, Fatemeh Fallah Tafti   +4 more
openalex   +1 more source

Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study [PDF]

, 2013
H. Takeuchi, Takefumi Suzuki, G. Remington, Robert R. Bies, Takayuki Abe, Ariel Graff‐Guerrero, Koichiro Watanabe, M. Mimura, H. Uchida   +8 more
openalex   +1 more source

An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 103-111, January 2026.
Abstract Aims Ulotaront is an investigational trace amine‐associated receptor 1 (TAAR1) agonist demonstrated to slow gastric emptying in schizophrenia patients with metabolic syndrome (MetSyn) and prediabetes type 2. Here we evaluate the effects of ulotaront on glucose‐insulin dynamics in schizophrenia patients with MetSyn and prediabetes.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Yu‐Luan Chen, Yongquan Lai, Manu Chakravarthy, Clay Dehn, Kenneth Koblan, Seth C. Hopkins   +10 more
wiley   +1 more source

Risperidone-Induced Leukopenia in a Patient with Epilepsy and Sjögren’s Synd- rome: A Case Report [PDF]

, 2019
Yichun Liu, Jan Brandt
openalex   +1 more source

Regular Medications Administered to Older Adults in Aged Care Facilities: A Retrospective Descriptive Study

Journal of Clinical Nursing, Volume 35, Issue 1, Page 363-374, January 2026.
ABSTRACT Aim(s) To explore which regularly prescribed medications are most commonly administered to older adults in aged care facilities in Australia, by whom and when, and to identify the prevalence of polypharmacy in this population group. Design Retrospective descriptive study.
Stephanie M. Garratt, Maneesh Prasad, Kelly Ottosen, Elizabeth Manias   +3 more
wiley   +1 more source

Ensuring generalizability and clinical utility in mental health care applications: Robust artificial intelligence‐based treatment predictions in diverse psychosis populations

Psychiatry and Clinical Neurosciences, Volume 80, Issue 1, Page 64-75, January 2026.
Aim Artificial Intelligence (AI)‐based prediction models of treatment response promise to revolutionize psychiatric care by enabling personalized treatment, but very few have been thoroughly tested in different samples or compared to current clinical standards.
Fiona Coutts, Sergio Mena, Esin Ucur, W Wolfgang Fleischhacker, Rene Kahn, Jeffrey Lieberman, Alkomiet Hasan, Oliver Howes, Christoph Correll, Nikolaos Koutsouleris, Paris Alexandros Lalousis   +10 more
wiley   +1 more source

Effect of body-oriented psychological therapy on negative symptoms in schizophrenia: a randomized controlled trial [PDF]

, 2006
Priebe, S, Rohricht, F
core   +1 more source